Disease-Screening Biomarkers: Cancer & Cardiac Explained

What Makes a Biomarker "Disease-Specific"

In this context, a biomarker is any measurable substance — usually in blood, but sometimes urine, tissue, or imaging findings — whose level or presence correlates with a specific disease process. Disease-screening biomarkers generally fall into a few categories: tumor markers used alongside imaging and biopsy in certain cancers (like PSA for prostate cancer, which we cover separately at PSA levels); cardiac biomarkers like troponin and BNP that rise during a heart attack or heart failure; markers of organ function (elevated liver enzymes, declining kidney eGFR); and emerging markers under active research for neurodegenerative disease, such as specific proteins studied in Alzheimer's disease diagnosis.

Almost none of these are used as a standalone diagnosis. A cancer biomarker that's elevated doesn't mean a person has cancer, and a normal result doesn't rule it out — these tests are one input alongside imaging, biopsy, symptoms, and clinical judgment. That's a meaningfully different use case than the proactive wellness tracking most of this site discusses, where a marker like fasting insulin is genuinely actionable and trackable on its own over time.

Cardiac Biomarkers

The best-known example is troponin, a protein released into the bloodstream when heart muscle is damaged. It's the primary blood test used in emergency departments to confirm or rule out a heart attack, typically drawn serially over several hours because levels rise progressively after cardiac injury. BNP (B-type natriuretic peptide) is another cardiac biomarker, released when the heart is under strain, and is used to help diagnose and monitor heart failure. Neither of these is something to self-order for routine wellness tracking — they're acute-care tools, used when there's clinical suspicion of a cardiac event, not proactive screening markers for an otherwise healthy person. If you're experiencing chest pain, shortness of breath, or other symptoms of a possible heart attack, seek emergency care immediately rather than researching biomarkers.

Cancer, Kidney, Liver, and Neurodegenerative Markers

Cancer: Tumor markers (like CA-125, CEA, or PSA) can be elevated in certain cancers but are also elevated by many benign conditions, which is why they're used to monitor known disease or alongside imaging and biopsy — rarely as a standalone screening tool in an otherwise asymptomatic person, with a few specific exceptions your doctor would guide you on.

Kidney and liver: These are markers this site already covers in more practical depth — see our guides to kidney function testing (eGFR, creatinine) and liver function testing (ALT, AST) for how routine organ-function screening actually works, since these are commonly included in a standard metabolic panel rather than being specialty-only tests.

Neurodegenerative disease: Research into blood-based biomarkers for Alzheimer's disease (measuring specific proteins associated with the disease process) has advanced significantly in recent years and is beginning to move from research settings into limited clinical use, typically ordered by a neurologist as part of a broader diagnostic workup rather than as a standalone consumer test.